Case Western Reserve to lead $14.7M NIH sprint study network in Ohio

October 29, 2009

Case Western Reserve University School of Medicine has received a $14.7 million, nine-year contract from the National Institutes of Health to be one of five institutions to lead a trial to determine if lowering systolic blood pressure in hypertensive patients, without diabetes, to below the currently recommended level can reduce the incidence of cardiovascular and kidney disease and slow cognitive decline. Case Western Reserve will head a Clinical Center Network (CCN) consisting of investigators from its School of Medicine and three other Northeast Ohio clinical centers, as well as The Ohio State University College of Medicine. It will be directed by Jackson T. Wright, Jr., M.D., Ph.D., Professor of Medicine, Case Western Reserve and Director of the Clinical Hypertension Program at University Hospitals Case Medical Center (UHCMC).

"The objective of the study is to evaluate whether treating patients to systolic blood pressure of less than 120 mmHg reduces the risk of cardiovascular and kidney disease, or age-related cognitive decline, more than the usually recommended level of less than 140 mmHg," says Dr. Wright. "We suspect that treating to the lower level of 120 mmHg will result in fewer cardiovascular and kidney complications. However, this needs to be proven."

The results of this study will grow the small body of evidence supporting this hypothesis. Called SPRINT (Systolic Blood Pressure Intervention Trial), the study findings will be used to reevaluate the optimal blood pressure for patients and have the potential to establish new guidelines for healthcare providers. SPRINT will enroll approximately 7,500 participants, age 55 or older, with systolic blood pressure of 130 mm Hg or higher. All participants will have a history of cardiovascular disease or be at high risk for heart disease by having at least one additional risk factor, except diabetes; between 40- and 50 percent will have chronic kidney disease. Blacks and other minorities will comprise at least 30 percent of the study. The Case Western Reserve CCN will recruit approximately 1,500 patients.

A very important sub-study of SPRINT will evaluate how the higher versus lower blood pressure goals affect cognition function and dementia. Alan Lerner, M.D., Professor of Neurology, and Director of the Memory and Cognition Center at UHCMC will lead the Case Western Reserve University efforts for this cognitive functioning sub-study, called SPRINT-MIND.

The Case Western Reserve CCN is a network consisting of the major academic medical centers in Northeast Ohio and The Ohio State University College of Medicine; the clinical centers and investigators in the CCN include: SPRINT study investigators will make substantial use of the resources available through the Clinical and Translational Science Awards (CTSA) at each university: the Clinical & Translational Science Collaborative at Case Western Reserve University and The Ohio State University Center for Clinical and Translational Science. These CTSA grants are NIH-funded consortiums designed to transform how clinical and translational research is conducted, with the goal of enabling researchers to provide new treatments to patients more efficiently and quickly. Both CTSAs will assist in the recruitment of SPRINT study patients and the monitoring of participants.

"SPRINT is an important comparative effectiveness clinical trial," said Elizabeth G. Nabel, M.D., Director of the NIH's National Heart, Lung, and Blood Institute (NHLBI), the lead funder of the study. "The results will help patients and their doctors determine whether more aggressive blood pressure treatment is beneficial in reducing overall deaths, heart attacks, strokes, kidney failure, or age-related cognitive decline."
-end-
SPRINT is funded by the NHLBI and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Two other NIH institutes - the National Institute of Neurological Disorders and Stroke (NINDS), and the National Institute on Aging (NIA) - are funding SPRINT-MIND.



About Case Western Reserve University School of Medicine


Founded in 1843, Case Western Reserve University School of Medicine is the largest medical research institution in Ohio and is among the nation's top medical schools for research funding from the National Institutes of Health. The School of Medicine is recognized throughout the international medical community for outstanding achievements in teaching. The School's innovative and pioneering Western Reserve2 curriculum interweaves four themes--research and scholarship, clinical mastery, leadership, and civic professionalism--to prepare students for the practice of evidence-based medicine in the rapidly changing health care environment of the 21st century. Eleven Nobel Laureates have been affiliated with the school.

Annually, the School of Medicine trains more than 800 M.D. and M.D./Ph.D. students and ranks in the top 25 among U.S. research-oriented medical schools as designated by U.S. News &World Report "Guide to Graduate Education."

The School of Medicine's primary affiliate is University Hospitals Case Medical Center and is additionally affiliated with MetroHealth Medical Center, the Louis Stokes Cleveland Department of Veterans Affairs Medical Center, and the Cleveland Clinic, with which it established the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University in 2002. http://casemed.case.edu.

Case Western Reserve University

Related Kidney Disease Articles from Brightsurf:

Waistline matters in kidney disease
Does fat matter in kidney disease? The investigators found that all measures of higher abdominal fat content (including visceral fat, liver fat, or subcutaneous fat) and slower walk times were associated with increased levels of cardiometabolic risk factors in adults with non-dialysis dependent kidney disease.

Reducing urinary protein for patients with rare kidney disease slows kidney decline
New findings show that reducing the amount of protein in the urine of patients with focal segmental glomerulosclerosis can significantly slow declines in kidney function and extend time before patients' kidneys fail.

Antioxidant agent may prevent chronic kidney disease and Parkinson's disease
Researchers from Osaka University developed a novel dietary silicon-based antioxidant agent with renoprotective and neuroprotective effects.

Acute kidney injury and end stage kidney disease in severe COVID-19
Many COVID-19 patients experience hematuria, proteinuria and elevated serum creatinine concentration early in the course of the disease.

Genes tell a story about diabetic kidney disease
Studying Finnish genes leads to unique revelations about the development of a serious complication of diabetes, and informs an ongoing genomic study of a Singaporean cohort as part of Singapore's Diabetes Study in Nephropathy and other Microvascular Complications (DYNAMO).

New study provides insight into chronic kidney disease
Researchers have further analyzed a known signaling pathway they believe brings them one step closer to understanding the complex physiology of patients with chronic kidney disease (CKD), which might provide a path to new treatment options.

Predicting risk of chronic kidney disease
Data from about 5 million people (with and without diabetes) in 28 countries were used to develop equations to help identify people at increased five-year risk of chronic kidney disease, defined as reduced estimated glomerular filtration rate (eGFR).

A healthy diet may help prevent kidney disease
In an analysis of published studies, a healthy dietary pattern was associated with a 30% lower incidence of chronic kidney disease.

Is kidney failure a man's disease?
A new analysis of the ERA-EDTA Registry [1] reveals a striking gender difference in the incidence and prevalence of end-stage renal disease.

Chronic kidney disease: Everyone's concern
850 million people worldwide are affected by kidney disease. This worrying figure was published last June.

Read More: Kidney Disease News and Kidney Disease Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.